AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG
Contact:
Dr. Christoph Klade
Phone:
E-Mail: christoph.klade@aoporphan.com
KEYWORDS:
  • EMA
  • Ropeginterferon alfa-2b
  • AOP Orphan Pharmaceuticals AG
Download Photos
AOP Orphan Pharmaceuticals AG (3 releases)

AOP Orphan Pharmaceuticals AG announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera [more]

AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations